Results 51 to 60 of about 1,862 (162)

Neurologic and psychiatric features of impending neurodegeneration in iRBD

Clinical Parkinsonism & Related Disorders, 2023
Introduction: Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is linked to Parkinson’s disease and other alpha-synucleinopathies, but various subsets of iRBD may not carry equal risk (i.e., those with depression are at higher risk than
Daniel A. Barone, Harini Sarva, Natalie Hellmers, Fei Wang, Zhenxing Xu, Ana C. Krieger, Claire Henchcliffe   +6 more
doaj   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 753-761, September 2026.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Precision medication: An illustrative case series guiding the clinical application of multi‐drug interactions and pharmacogenomics

Clinical Case Reports, 2020
Precision medication entails selecting the precise medication, dose, and timing of administration. Multi‐drug interactions and genetics significantly affect precision medication. In this article, we present two simulated cases for real‐world applications
Kevin T. Bain, David McGain, Emily J. Cicali, Calvin H. Knowlton, Veronique Michaud, Jacques Turgeon   +5 more
doaj   +1 more source

Cognitive training and promoting a healthy lifestyle in isolated REM sleep behavior disorder: The randomized controlled trial CogTrAiL‐RBD

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal phase of Lewy body diseases and linked to a high risk for cognitive decline. Therefore, iRBD provides a suitable window for early intervention. METHODS In the monocentric randomized controlled trial “Cognitive Training & a Healthy, Active Lifestyle ...
Anja Ophey, Sinah Röttgen, Konstantin Kufer, Julia Pauquet, Daniel Scharfenberg, Philipp Armbrust, Anastasia Kammerzell, Nathalie Knopf, Sandy Kollath, Philipp Sommer, Christopher E. J. Doppler, Ezequiel Farrher, Aline Seger, N. Jon Shah, David Zopfs, Kathrin Reetz, Gereon R. Fink, Michael Sommerauer, Elke Kalbe   +18 more
wiley   +1 more source

Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder

Journal of Parkinson’s Disease, 2023
Background: Idiopathic rapid eye movement sleep behavior disorder (iRBD) is increasingly recognized as a manifestation preceding the α-synucleinopathies like Parkinson’s disease (PD).
Xuan Zhang, Li Ma, Danqi Liang, Bingxin Song, Jingshan Chen, Yaqin Huang, Lin Xu, Peng Zhao, Wei Wu, Nan Zhang, Rong Xue   +10 more
doaj   +1 more source

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 492-500, August 2026.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel, Anina Zumtaugwald, Anna Bollinger, Chiara Jeiziner, Kurt E. Hersberger, Florine Wiss, Markus L. Lampert, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble   +9 more
wiley   +1 more source

Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion

PLOS ONE, 2016
Resveratrol, a phytoalexin found in berries, peanuts, grapes, and red wine, inhibits oxidation, inflammation, and cell proliferation and collagen synthesis in multiple cell types and or animal models. It represses collagen deposition in the vasculature, heart, lung, kidney, liver, and esophagus in animal models and may have some utility as an anti ...
Mehrnaz Gharaee-Kermani, Bethany B Moore, Jill A Macoska   +2 more
openaire   +4 more sources

Generalized EEG Slowing Across Phasic REM Sleep, Not Subjective RBD Severity, Predicts Neurodegeneration in Idiopathic RBD

Nature and Science of Sleep, 2022
Si-Yi Gong,1,* Yun Shen,1,* Han-Ying Gu,1 Sheng Zhuang,1 Xiang Fu,1,2 Qiao-Jun Wang,1 Cheng-Jie Mao,1 Hua Hu,1 Yong-Ping Dai,1 Chun-Feng Liu1– 3 1Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated ...
Gong SY, Shen Y, Gu HY, Zhuang S, Fu X, Wang QJ, Mao CJ, Hu H, Dai YP, Liu CF   +9 more
doaj  

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Autonomic dysfunction and phenoconversion in idiopathic REM sleep behavior disorder

Clinical Autonomic Research, 2020
REM sleep behavior disorder (RBD) is a common finding among patients with synucleinopathies. We aimed to determine the degree of autonomic dysfunction in patients presenting with idiopathic RBD (iRBD), and the predictive value of autonomic dysfunction for phenoconversion to a defined neurodegenerative disease.We searched our electronic medical record ...
Stuart J, McCarter, Tonette L, Gehrking, Erik K, St Louis, Mariana D, Suarez, Bradley F, Boeve, Michael H, Silber, Phillip A, Low, Wolfgang, Singer   +7 more
openaire   +3 more sources